Proactive Investors - Run By Investors For Investors

Redx Pharma appoints CFO as it publishes annual results

Dr James Mead joins the life sciences company on February 1
boardroom table
Redx will have a new face around the boardroom table

Redx Pharma Plc (LON:REDX) pharma announced the appointment of a new chief financial officer at the same as presenting its figures for the last financial year.

Dr James Mead, who has held senior roles at AstraZeneca, will take over from interim incumbent Dominic Jackson on February 1.

READ: Redx Pharma hails new fibrosis drug candidate

"I am delighted to have James join our team at Redx. He will bring a dynamic and professional approach and will play an integral role as we focus on progressing delivery of our strategy,” said chief executive Lisa Anson.

The 41-year-old joins the business at an exciting. Having defined a new strategy under the guidance chairman Iain Ross after a period in administration, Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.

Treatments for cancer and fibrosis 

Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.

Financially, the benchmark for small drug discovery groups such as Redx is cash in the bank. As at the period-end it had £6.5mln, the equivalent of three-quarters of the company’s current market capitalisation.

As is common for businesses at this early stage of development, Redx was loss-making. The deficit for the year ended September 30 was £8.8mln, with operating expenditure reduced £5.2mln to £10.6mln.

Chairman Ross said: "This set of results confirms that Redx is operationally a stronger and leaner company led by an ambitious new management team, with a clear strategic direction. 

“Lisa Anson has made a major impact and under her leadership, the group is starting to make real progress in our programmes aimed at creating high-value drugs that treat significant unmet need in cancer and fibrosis.”

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use